Thiopurines and risk of nonmelanoma skin cancer in inflammatory bowel disease

JAMA Dermatology

Volumn 149, Issue 1, 2013, Pages 92-94

  Ramiscal, Judi Anne B ^b   Brewer, Jerry D ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; NOTE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SKIN CANCER; SOCIAL STATUS; SQUAMOUS CELL CARCINOMA;

EID: 84873435002     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.616     Document Type: Note

References (12)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-287.
2. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1-3):8-18. (Pubitemid 33040718)
3. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979;2(6203):1461-1466. (Pubitemid 10162309)
4. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141(5):1612-1620.
5. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al; Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621-1628.
6. Jess T. Thiopurines for inflammatory bowel disease: time to engage with dermatologists? Gastroenterology. 2011;141(5):1549-1551.
7. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8(3):268-274.
8. Van Schaik FD, Van Oijen MG, Smeets HM, Van der Heijden GJ, Siersema PD, Oldenburg B. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol. 2011;9(5):449-451.
9. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol. 2012;27(2):385-389.
10. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691. (Pubitemid 36459475)
11. Beaugerie L, Brousse N, Bouvier AM, et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617-1625.
12. Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sørensen HT. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol. 2010;90(5):474-479.